<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="editorial" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1535</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕРОПРИЯТИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EVENTS</subject></subj-group></article-categories><title-group><article-title>Конгресс «Химико-фармацевтические и биологические препараты: фармацевтическая и клиническая разработка согласно правилам ЕАЭС»</article-title><trans-title-group xml:lang="en"><trans-title>Congress "Chemical-pharmaceutical and Biological Preparations: Pharmaceutical and Clinical Development in Accordance with the Rules of the EAEU"</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Редакционная</surname><given-names>статья</given-names></name><name name-style="western" xml:lang="en"><surname>Editorial</surname><given-names>Article</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>28</day><month>08</month><year>2023</year></pub-date><volume>12</volume><issue>3</issue><fpage>27</fpage><lpage>28</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Редакционная с., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Редакционная с.</copyright-holder><copyright-holder xml:lang="en">Editorial a.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1535">https://www.pharmjournal.ru/jour/article/view/1535</self-uri><abstract><p>Конгресс «Химико-фармацевтические и биологические препараты: фармацевтическая и клиническая разработка согласно правилам ЕАЭС» пройдет в Москве 22 сентября в конгресс-центре Сеченовского Университета. Тематика мероприятия традиционно охватывает все жизненные этапы лекарственного средства, начиная от разработки и заканчивая пострегистрационными исследованиями ЛС.</p></abstract><trans-abstract xml:lang="en"><p>The Congress "Chemical and Biological Drugs: Pharmaceutical and Clinical Development in Accordance with the EAEU rules" will be held in Moscow on September 22 at the Sechenov University Congress Center. The theme of the event traditionally covers all life stages of a medicinal product, from development to post-registration studies of drugs.</p></trans-abstract></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
